|
Market Closed -
Australian S.E.
10:10:02 13/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 9.590 AUD | +0.95% |
|
+2.79% | -23.03% |
| Market Cap | 484M 341M 296M 277M 253M 476M 32.59B 3.27B 1.28B 16.31B 1.28B 1.25B 54.41B | P/E 2026 * |
13.5x | P/E 2027 * | 12.8x |
|---|---|---|---|---|---|
| Enterprise Value | 231M 163M 141M 132M 121M 227M 15.56B 1.56B 609M 7.79B 612M 599M 25.98B | EV / Sales 2026 * |
2.33x | EV / Sales 2027 * | 1.9x |
| Free-Float |
83.79% | Yield 2026 * |
0.64% | Yield 2027 * | 0.83% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | +0.95% | ||
| 1 week | +2.79% | ||
| Current month | +5.85% | ||
| 1 month | -6.62% | ||
| 3 months | +2.46% | ||
| 6 months | -10.54% | ||
| Current year | -23.03% |
| 1 week | 9.2 |  | 9.76 |
| 1 month | 8.77 | | 10.42 |
| Current year | 8.35 | | 13.48 |
| 1 year | 8.35 | | 14 |
| 3 years | 8.35 | | 21.45 |
| 5 years | 8.35 | | 44.67 |
| 10 years | 4.95 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03/10/24 | Buy | Director | 8,333 | 0.0166% | ||
| 27/11/23 | Fiscal year | Chief Executive Officer | 301,125 | 0.6094% | ||
| 27/11/23 | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.95% | +2.79% | -20.68% | -51.74% | 339M | |
| +1.00% | +4.39% | +43.53% | -0.30% | 79.68B | |
| +0.97% | +4.90% | -0.37% | +26.99% | 50.61B | |
| -1.22% | -4.41% | +17.13% | +167.13% | 48.81B | |
| -0.66% | +5.25% | -47.97% | -48.32% | 46.91B | |
| +0.85% | +2.12% | +55.82% | -22.77% | 30.86B | |
| -0.03% | +18.18% | +136.71% | -36.35% | 25.42B | |
| -0.21% | +1.81% | +40.38% | +84.73% | 24.48B | |
| -0.42% | +5.37% | +8.99% | +187.03% | 21.2B | |
| -3.14% | -1.92% | +61.19% | +157.40% | 16.39B | |
| Average | -0.05% | +3.20% | +29.47% | +46.38% | 34.47B | |
| Weighted average by Cap. | +0.11% | +2.91% | +27.29% | +41.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.21M 70.04M 60.71M 56.91M 51.89M 97.64M 6.68B 670M 262M 3.35B 263M 257M 11.16B | 105M 73.85M 64.01M 60.01M 54.72M 103M 7.05B 707M 276M 3.53B 277M 271M 11.77B |
| Net income | 35.72M 25.22M 21.86M 20.49M 18.68M 35.16M 2.41B 241M 94.19M 1.2B 94.67M 92.62M 4.02B | 37.66M 26.59M 23.05M 21.6M 19.7M 37.07M 2.54B 254M 99.31M 1.27B 99.82M 97.66M 4.24B |
| Net Debt | -253M -178M -155M -145M -132M -249M -17.03B -1.71B -666M -8.52B -670M -655M -28.43B | -285M -201M -174M -163M -149M -280M -19.18B -1.92B -751M -9.6B -754M -738M -32.02B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/08/26 | A$9.590 | +0.95% | 78,621 |
| 12/08/26 | A$9.500 | -2.16% | 93,054 |
| 11/08/26 | A$9.710 | +0.94% | 55,054 |
| 10/08/26 | A$9.620 | +1.91% | 66,738 |
| 07/08/26 | A$9.440 | +0.75% | 55,430 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
